var data={"title":"Sirolimus: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sirolimus: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6955?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sirolimus-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sirolimus: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sirolimus-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sirolimus: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709411\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Immunosuppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving sirolimus should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Liver transplantation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss in a study in <i>de novo</i> liver transplant patients. Many of these patients had evidence of infection at or near the time of death. In this and another study in <i>de novo </i>liver transplant recipients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in hepatic artery thrombosis; most cases of hepatic artery thrombosis occurred within 30 days post-transplantation, and most led to graft loss or death. The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver transplant patients; therefore, use in these patients is not recommended.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lung transplantation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <i>de novo</i> lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen. The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in lung transplant patients; therefore, use in these patients is not recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221226\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rapamune</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221227\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rapamune</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221253\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        mTOR Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221230\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphangioleiomyomatosis:</b> Adults: Oral: Initial: 2 mg once daily. Obtain trough concentration in 10 to 20 days; adjust dose to maintain a target concentration of 5 to 15 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for lymphangioleiomyomatosis:</b> Once the maintenance dose is adjusted, further adjustments should be made at 7- to 14-day intervals to account for the long half-life of sirolimus. In general, dose proportionality may be assumed. New sirolimus dose <b>equals</b> current dose <b>multiplied by</b> (target concentration <b>divided by</b> current concentration). Once a stable dose is achieved, trough concentrations should be assessed at least every 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (rejection prophylaxis):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Low-to-moderate immunologic risk: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;40 kg: Loading dose: 3 mg/m<sup>2</sup> on day 1, followed by maintenance dosing of 1 mg/m<sup>2</sup> once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;40 kg: Loading dose: 6 mg on day 1; maintenance: 2 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>High immunologic risk: </b>Loading dose: Up to 15 mg on day 1; maintenance: 5 mg/day; obtain trough concentration between days 5 to 7 and adjust accordingly. Continue concurrent cyclosporine/sirolimus/corticosteroid therapy for 1 year following transplantation. Further adjustment of the regimen must be based on clinical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for renal transplantation:</b> Sirolimus dosages should be adjusted in small increments to maintain 24-hour trough concentrations within desired range based on risk and concomitant therapy. Dosage should be adjusted at intervals of 7 to 14 days to account for the long half-life of sirolimus. Maximum loading dose: 40 mg/day (although typical loading doses are not generally this high). Whole blood concentrations should not be used as the sole basis for dosage adjustment (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance therapy after withdrawal of cyclosporine:</b> According to the manufacturer, cyclosporine withdrawal is not recommended in high immunological risk renal transplant patients. Following 2 to 4 months of combined therapy, withdrawal of cyclosporine may be considered in low-to-moderate immunologic risk patients. Cyclosporine should be discontinued over 4 to 8 weeks, and a necessary increase in the dosage of sirolimus (up to fourfold) should be anticipated due to removal of metabolic inhibition by cyclosporine and to maintain adequate immunosuppressive effects. Dose-adjusted trough target concentrations are typically 16 to 24 ng/mL for the first year post-transplant and 12 to 20 ng/mL thereafter (per the manufacturer; measured by chromatographic methodology). Target trough concentrations of ~5 to 15 ng/mL are often used in clinical practice (Kahan 2000; Stenton 2005); refer to specific institutional protocol for target sirolimus trough concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Graft-versus-host disease (GVHD) (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GVHD (prevention):</b> 12 mg loading dose on day -3, followed by 4 mg daily (target trough level: 3 to 12 ng/mL); taper off after 6 to 9 months (Armand 2008; Cutler 2007). Additional trials may be necessary to further define the role of sirolimus in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment of refractory acute GVHD:</b> 4 to 5 mg/m<sup>2</sup> for 14 days (no loading dose) (Benito 2001). Additional trials may be necessary to further define the role of sirolimus in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment of chronic GVHD:</b> 6 mg loading dose, followed by 2 mg daily (target trough level: 7 to 12 ng/mL) for 6 to 9 months (Couriel 2005). Additional trials may be necessary to further define the role of sirolimus in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart transplantation (</b>\n      <b>prophylaxis of organ rejection and allograft vasculopathy)<b> (off-label use):</b></b> Oral: <b>Note:</b> The use of sirolimus in the immediate post-cardiac transplant period (ie, <i>de novo</i> heart transplant) as a primary immunosuppressant has fallen out of favor due to adverse effects (eg, impaired wound healing and infection); however, patients may be converted to sirolimus from a calcineurin inhibitor (after at least 6 months from time of transplant [Costanzo 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from a calcineurin inhibitor (CNI) (ie, cyclosporine, tacrolimus):</i> Reduce cyclosporine by 25 mg twice daily or tacrolimus by 1 mg twice daily followed by initiation of sirolimus 1 mg once daily; adjust sirolimus dose to target trough level of 8 to 14 ng/mL, withdraw CNI, repeat biopsy 2 weeks after CNI withdrawal (Topilsky 2012). Alternatively, maintain CNI concentrations and initiate sirolimus 1 mg once daily for 1 week; adjust sirolimus to target trough levels of 10 to 15 ng/mL over 2 weeks, then reduce CNI to target 50% of therapeutic concentrations and after 2 weeks evaluate for rejection. If no rejection, continue same regimen for an additional month, then reduce CNI to 25% of therapeutic concentrations with repeat biopsy 2 weeks later; if no rejection, may discontinue CNI after 2 weeks and continue to maintain sirolimus trough levels of 10 to 15 ng/mL (usual doses required to maintain target levels: 1 to 8 mg daily) (Kushwaha 2005). Refer to specific institutional protocol for target sirolimus trough concentrations; trough will vary based on time from transplant, assay method, and concurrent or transitioning therapies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from antiproliferative immunosuppressive drug (ie, azathioprine or mycophenolate) while maintaining calcineurin inhibitor:</i> Upon discontinuation of antiproliferative, administer sirolimus 6 mg loading dose followed by 2 mg once daily titrated to a target trough level of 4 to 15 ng/mL (Mancini 2003) or 4 to 12 ng/mL per ISHLT recommendations (Costanzo 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplantation (rejection prophylaxis) (off-label use):</b> Oral: Initial loading dose: 5 mg once, followed by a maintenance dose of 3 mg once daily; titrate to a target trough level of 5 to 13 ng/mL (Snell 2002). Do not initiate sirolimus until after the bronchial anastomosis has completely healed (approximately 90 days) due to potential fatal airway dehiscence with earlier initiation (King-Biggs 2003). Additional trials may be necessary to further define the role of sirolimus in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal angiomyolipoma (off-label use):</b> Oral: Initial: 0.5 mg/m<sup>2</sup> once daily titrated to a target trough level of 3 to 6 ng/mL (may increase to target trough level of 6 to 10 ng/mL if &lt;10% reduction in lesion diameters at 2 months) for 2 years (Davies 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221242\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sirolimus-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sirolimus: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Renal transplant (rejection prophylaxis): Low-to-moderate immunologic risk:</b> Adolescents &ge;13 years: Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221231\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221232\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is necessary. However, adjustment of regimen (including discontinuation of therapy) should be considered when used concurrently with cyclosporine and elevated or increasing serum creatinine is noted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221233\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Loading dose: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maintenance dose: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate impairment (Child-Pugh classes A and B): Reduce maintenance dose by ~33%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment (Child-Pugh class C): Reduce maintenance dose by ~50%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221201\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rapamune: 1 mg/mL (60 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rapamune: 0.5 mg, 1 mg, 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50215677\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rapamune: 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11310396\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021083s058,021110s075lbl.pdf#page=52&amp;token=kJAC80Ianm2acD5sas7t+zdV4pcbWHDuciEQhgoO1TLZg2pwC95BksyyiCgtBgu7IztdzLmlWiodvhvoox3kHtj+vBVVeoYYXkppg6rjYKW/c8QhsqDYTF3Q/Pe7vvWe&amp;TOPIC_ID=10329\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021083s058,021110s075lbl.pdf#page=52</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221204\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer consistently (either with or without food). <i>Renal transplant:</i> Sirolimus should be taken 4 hours after oral cyclosporine (Neoral or Gengraf).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution: Mix (by stirring vigorously) with at least 60 mL of water or orange juice. No other liquids should be used for dilution. Patient should drink diluted solution immediately. The cup should then be refilled with an additional 120 mL of water or orange juice, stirred vigorously, and the patient should drink the contents at once.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Do not crush, split, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133426\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221203\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphangioleiomyomatosis:</b> Treatment of lymphangioleiomyomatosis. Therapeutic drug monitoring is recommended for all patients receiving sirolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplantation (rejection prophylaxis):</b> Prophylaxis of organ rejection in patients receiving renal transplants (in low-to-moderate immunologic risk patients in combination with cyclosporine and corticosteroids with cyclosporine withdrawn 2 to 4 months after transplant, and in high immunologic risk patients in combination with cyclosporine and corticosteroids for the first year after transplant). Therapeutic drug monitoring is recommended for all patients receiving sirolimus. High immunologic risk renal transplant patients are defined (per the manufacturer's labeling) as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft based on an immunologic process and/or patients with high PRA (panel-reactive antibodies; peak PRA level &gt;80%).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use (renal transplantation): Cyclosporine withdrawal has not been studied in patients with Banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, patients who are dialysis-dependent, patients with serum creatinine &gt;4.5 mg/dL, Black patients, patients with multiorgan transplants or secondary transplants, or those with high levels of PRA. In patients at high immunologic risk, the safety and efficacy of sirolimus used in combination with cyclosporine and corticosteroids have not been studied beyond 1 year; therefore, after the first 12 months following transplantation, consider any adjustments to the immunosuppressive regimen on the basis of the clinical status of the patient. The safety and efficacy of sirolimus have not been established in patients younger than 13 years or in pediatric renal transplant patients younger than 18 years who are considered at high immunologic risk. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the care of renal transplant recipients recommend not initiating sirolimus until graft function has been established and surgical wounds have healed (KDIGO 2009). Avoid the use of sirolimus in combination with calcineurin inhibitors, particularly in the early post transplant period due to an increased risk of nephrotoxicity (KDIGO 2009; Webster 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471667\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chordoma (advanced); Graft-versus-host disease (GVHD) prevention; Acute GVHD (treatment); Chronic GVHD treatment; Heart transplant (prophylaxis of organ rejection and allograft vasculopathy); Lung transplantation (rejection prophylaxis); Renal angiomyolipoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4288698\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rapamune may be confused with Rapaflo</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sirolimus may be confused with everolimus, pimecrolimus, silodosin, tacrolimus, temsirolimus</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221193\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of many adverse effects is dose related. Reported events exclusive to renal transplant patients unless otherwise noted. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema (&ge;20% to 58%, LAM and renal transplants), hypertension (49%), edema (18% to 20%), chest pain (LAM), deep vein thrombosis, pulmonary embolism, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (&ge;20% to 34%, LAM and renal transplants), pain (29% to 33%), dizziness (LAM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris (&ge;20% to 22%, LAM and renal transplants), skin rash (10% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypertriglyceridemia (45% to 57%), hypercholesterolemia (&ge;20% to 46%, LAM and renal transplants), amenorrhea, diabetes mellitus, hypermenorrhea, hypervolemia, hypokalemia, increased lactate dehydrogenase, menstrual disease, ovarian cyst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation (36% to 38%), abdominal pain (&ge;20% to 36%, LAM and renal transplants), diarrhea (&ge;20% to 35%, LAM and renal transplants), nausea (&ge;20% to 31%, LAM and renal transplants), stomatitis (3% to &gt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (23% to 33%), thrombocytopenia (14% to 30%), lymphoproliferative disorder (&le;3%; including lymphoma), skin carcinoma (&le;3%; includes basal cell carcinoma, squamous cell carcinoma, melanoma), hemolytic-uremic syndrome, leukopenia, lymphocele, thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes simplex infection, herpes zoster, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (25% to 31%), myalgia (LAM), osteonecrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine (39% to 40%), pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis (LAM), epistaxis, pneumonia, upper respiratory tract infection (LAM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;3%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylactoid reaction, anaphylaxis, angioedema, ascites, azoospermia, cardiac tamponade, cytomegalovirus, dehiscence (fascial), Epstein-Barr infection, exfoliative dermatitis, fluid retention, focal segmental glomerulosclerosis, gingival hyperplasia, hepatic necrosis, hepatotoxicity, hyperglycemia, hypersensitivity angiitis, hypersensitivity reaction, hypophosphatemia, incisional hernia, increased serum ALT, increased serum AST, increased susceptibility to infection (including opportunistic), interstitial pulmonary disease (dose related; includes pneumonitis, pulmonary fibrosis, and bronchiolitis obliterans organizing pneumonia with no identified infectious etiology), joint disorders, lymphedema, Merkel cell carcinoma, mycobacterium infection, nephrotic syndrome, neutropenia, pancreatitis, pancytopenia, pericardial effusion, pleural effusion, pneumonia due to <i>Pneumocystis carinii</i>, progressive multifocal leukoencephalopathy, proteinuria, pseudomembranous colitis, pulmonary alveolitis, pulmonary hemorrhage, renal disease (BK virus-associated), reversible posterior leukoencephalopathy syndrome, tuberculosis, weight loss, wound dehiscence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221207\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sirolimus or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: Has been reported; risk is increased in patients with elevated sirolimus levels and/or concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors). Angioedema resolved following discontinuation or dose reduction in some cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Immunosuppressive agents, including sirolimus, increase the risk of infection.</b> Immune suppression may also increase the risk of opportunistic infections including activation of latent viral infections (including BK virus-associated nephropathy), fatal infections, and sepsis. Prophylactic treatment for <i>Pneumocystis jirovecii</i> pneumonia (PCP) should be administered for 1 year post-transplant; prophylaxis for cytomegalovirus (CMV) should be taken for 3 months post-transplant in patients at risk for CMV. Progressive multifocal leukoencephalopathy (PML), an opportunistic CNS infection caused by reactivation of the JC virus, has been reported in patients receiving immunosuppressive therapy, including sirolimus. Clinical findings of PML include apathy, ataxia, cognitive deficiency, confusion, and hemiparesis; promptly evaluate any patient presenting with neurological changes; consider decreasing the degree of immunosuppression with consideration to the risk of organ rejection in transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial lung disease: Cases of interstitial lung disease (ILD) (eg, pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], pulmonary fibrosis) have been observed (some fatal); may be associated with pulmonary hypertension (including pulmonary arterial hypertension) and risk may be increased with higher trough levels. ILD may resolve with dose reduction or discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: May increase serum lipids (cholesterol and triglycerides). Use with caution in patients with hyperlipidemia. Monitor cholesterol/lipids; if hyperlipidemia occurs, follow current guidelines for management (diet, exercise, lipid lowering agents). Antihyperlipidemic therapy may not be effective in normalizing levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphocele/fluid accumulation: Use has been associated with an increased risk of fluid accumulation and lymphocele. Peripheral edema, lymphedema, ascites, and pleural and pericardial effusions (including significant effusions and tamponade) were reported; use with caution in patients in whom fluid accumulation may be poorly tolerated, such as in cardiovascular disease (heart failure or hypertension) and pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Immunosuppressive agents, including sirolimus, may be associated with the development of lymphoma and other malignancies,</b> including an increased risk of skin cancer; limit sun and ultraviolet light exposure; use appropriate sun protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria: Increased urinary protein excretion has been observed when converting renal transplant patients from calcineurin inhibitors to sirolimus during maintenance therapy. A higher level of proteinuria prior to sirolimus conversion correlates with a higher degree of proteinuria after conversion. In some patients, proteinuria may reach nephrotic levels; nephrotic syndrome (new onset) has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: May increase serum creatinine and decrease GFR with long-term combination use of sirolimus and cyclosporine. Immunosuppressed patients are at an increased risk of BK viral-associated nephropathy which may impair renal function and cause graft loss; consider decreasing immunosuppressive burden if evidence of deteriorating renal function. Use with caution in patients concurrently taking medications which may alter renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound dehiscence/healing: May be associated with wound dehiscence and impaired healing; use caution in the perioperative period. Patients with a body mass index (BMI) &gt;30 kg/m<sup>2</sup> are at increased risk for abnormal wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; a reduction in the maintenance dose is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcineurin inhibitors: Concurrent use with a calcineurin inhibitor (cyclosporine, tacrolimus) may increase the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cyclosporine: Safety and efficacy of combination therapy with cyclosporine in high immunologic risk patients have not been studied beyond 12 months of treatment. Monitor renal function closely when combined with cyclosporine; consider dosage adjustment or discontinue in patients with increasing serum creatinine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Immunosuppressants may affect response to vaccination. Therefore, during treatment with sirolimus, vaccination may be less effective. The use of live vaccines should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver transplants: <b>[US Boxed Warning]: Sirolimus is not recommended for use in liver transplantation; studies indicate an association with an increased risk of hepatic artery thrombosis (HAT), graft failure, and increased mortality (with evidence of infection) in these patients when sirolimus is used in combination with cyclosporine and/or tacrolimus.</b> Most cases of HAT occurred within 30 days of transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lung transplants: <b>[US Boxed Warning]: Sirolimus is not recommended for use in lung transplantation. Bronchial anastomotic dehiscence cases have been reported in lung transplant patients when sirolimus was used as part of an immunosuppressive regimen; most of these reactions were fatal.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal transplant: In renal transplant patients, <i>de novo</i> use without cyclosporine has been associated with higher rates of acute rejection. Sirolimus may delay recovery of renal function in patients with delayed allograft function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Sirolimus tablets and oral solution are not bioequivalent, due to differences in absorption. Clinical equivalence was seen using 2 mg tablet and 2 mg solution. It is not known if higher doses are also clinically equivalent. Monitor sirolimus levels if changes in dosage forms are made.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: In renal transplant patients, sirolimus should be used in combination with cyclosporine (and corticosteroids) initially. Cyclosporine may be withdrawn in low-to-moderate immunologic risk patients after 2 to 4 months, in conjunction with an increase in sirolimus dosage. In high immunologic risk patients, use in combination with cyclosporine and corticosteroids is recommended for the first year. Adjustment of immunosuppressive therapy beyond 12 months should be considered based on clinical judgment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients. Adequate laboratory and supportive medical resources must be readily available.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory monitoring: Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Variations in methods to determine sirolimus whole blood concentrations, as well as interlaboratory variations, may result in improper dosage adjustments, which may lead to subtherapeutic or toxic levels. Determine the assay method used to assure consistency (or accommodations if changes occur), and for monitoring purposes, be aware of alterations to assay method or reference range and that values from different assays may not be interchangeable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221246\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221195\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10329&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Sirolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions may be required if used with boceprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Topical): May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED].  Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Sirolimus. Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sirolimus. Management: Consider avoiding concurrent use of sirolimus with strong CYP3A4 inhibitors in order to minimize the risk for sirolimus toxicity. Concomitant use of sirolimus and voriconazole or posaconazole is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Sirolimus. Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Sirolimus. Sirolimus may increase the serum concentration of Erythromycin (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Micafungin: May increase the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Sirolimus. Management: Avoid sirolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Sirolimus. Management: Carefully monitor the need for sirolimus dosage reductions when coadministered with nelfinavir.  Sirolimus dosage reduction will probably be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Sirolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the adverse/toxic effect of Sirolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May increase the serum concentration of Sirolimus. Management: Administer sirolimus at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of Sirolimus. Sirolimus may increase the serum concentration of Verapamil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Sirolimus.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221222\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Grapefruit juice may decrease clearance of sirolimus. Ingestion with high-fat meals decreases peak concentrations but increases AUC by 23% to 35%. Management: Avoid grapefruit juice. Take consistently (either with or without food) to minimize variability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221197\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221210\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Effective contraception must be initiated before therapy with sirolimus and continued for 12 weeks after discontinuation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4288699\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sirolimus is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221199\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor LFTs and CBC during treatment. Monitor sirolimus levels in all patients (especially in pediatric patients, patients &ge;13 years of age weighing &lt;40 kg, patients with hepatic impairment, or on concurrent potent inhibitors or inducers of CYP3A4 or P-gp, and/or if cyclosporine dosing is markedly reduced or discontinued), and when changing dosage forms of sirolimus. Also monitor serum cholesterol and triglycerides, blood pressure, serum creatinine, and urinary protein. Serum drug concentrations should be determined 3 to 4 days after loading doses and 7 to 14 days after dosage adjustments for renal transplant patients; however, these concentrations should not be used as the sole basis for dosage adjustment, especially during withdrawal of cyclosporine (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters). Monitor serum trough concentration 10 to 20 days after initiating therapy for lymphangioleiomyomatosis and 7 to 14 days after dosage adjustments. Once a stable dose is achieved, trough concentrations should be assessed at least every 3 months. <b>Note:</b> Concentrations and ranges are dependent on and will vary with assay methodology (chromatographic or immunoassay); assay methods are not interchangeable. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221202\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Determine the assay method used to assure consistency (or accommodations if changes occur) and for monitoring purposes, be aware of alterations to assay method or reference range. Refer to specific protocol for target sirolimus concentration goals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Serum trough concentration goals for renal transplantation (based on HPLC methods):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant cyclosporine: 4 to 12 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Low to moderate immunologic risk (after cyclosporine withdrawal): 8 to 12 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High immunologic risk (with cyclosporine): 10 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note: </b>Trough concentrations vary based on clinical context and use of additional immunosuppressants. The following represents typical ranges.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When combined with tacrolimus and mycophenolate mofetil (MMF) without steroids: 6 to 8 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">As a substitute for tacrolimus (starting 4 to 8 weeks post-transplant), in combination with MMF and steroids: 8 to 12 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Following conversion from tacrolimus to sirolimus &gt;6 months post-transplant due to chronic allograft nephropathy: 4 to 6 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum trough concentrations for heart transplantation (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">With calcineurin inhibitor (eg, cyclosporine): 4 to 12 ng/mL (Costanzo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Without calcineurin inhibitor: 10 to 15 ng/mL (Raichlin 2007a; Raichlin 2007b)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Following conversion from cyclosporine or tacrolimus to sirolimus: Initial (maintained until completion of conversion [~2 weeks]): 8 to 14 ng/mL (Topilsky 2012) <b>or</b> 9 to 15 ng/mL (Zuckermann 2012); Maintenance: 10 to 15 ng/mL (Kushwaha 2005) <b>or</b> 7 to 15 ng/mL (Zuckermann 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum trough concentrations for lymphangioleiomyomatosis: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum trough concentrations for GVHD prophylaxis in allogeneic stem cell transplant (off-label use): 3 to 12 ng/mL (Armand 2008; Cutler 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum trough concentrations for advanced chordoma (off-label use): 15 to 20 ng/mL (Stacchiotti 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum trough concentrations for renal angiomyolipoma (off-label use): 3 to 6 ng/mL; may increase to 6 to 10 ng/mL if &lt;10% reduction in lesion diameters at 2 months (Davies 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sirolimus inhibits T-lymphocyte activation and proliferation in response to antigenic and cytokine stimulation and inhibits antibody production. Its mechanism differs from other immunosuppressants. Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mechanistic target of rapamycin). This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. It inhibits acute rejection of allografts and prolongs graft survival.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In lymphangioleiomyomatosis, the mTOR signaling pathway is activated through the loss of the tuberous sclerosis complex (TSC) gene function (resulting in cellular proliferation and release of lymphangiogenic growth factors). By inhibiting the mTOR pathway, sirolimus prevents the proliferation of lymphangioleiomyomatosis cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221206\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 12 L/kg (range: 4 to 20 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~92%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive; in intestinal wall via P-glycoprotein and  hepatic via CYP3A4 to 7 major metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral solution: 14%; Oral tablet: 27% higher relative to the oral solution; oral solution and tablets are not bioequivalent however, clinical equivalence shown at 2 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 13.7 &plusmn; 6.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Mean: 62 hours (range: 46 to 78 hours); extended in hepatic impairment (Child-Pugh class A or B) to 113 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral solution: 1 to 3 hours; Tablet: 1 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (91% due to P-glycoprotein-mediated efflux into gut lumen); urine (2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221209\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rapamune Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (60 mL): $2,105.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Rapamune Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $1,754.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $3,508.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $7,017.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sirolimus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $847.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,694.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $3,149.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221212\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Rapacan (IN);</li>\n      <li>Rapalimus (JP);</li>\n      <li>Rapamune (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, KR, KW, LB, LT, LU, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VE, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antin J, Kim H, Cutler C, et al, &quot;Sirolimus, Tacrolimus, and Low-Dose Methotrexate for Graft-Versus-Host Disease Prophylaxis in Mismatched Related Donor or Unrelated Donor Transplantation,&quot; <i>Blood</i>, 2003, 102(5):1601-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/12730113/pubmed\" target=\"_blank\" id=\"12730113\">12730113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19001324\"></a>Armand P, Gannamaneni S, Kim HT, et al, &ldquo;Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning,&rdquo; <i>J Clin Oncol</i>, 2008, 26(35):5767-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/19001324/pubmed\" target=\"_blank\" id=\"19001324\">19001324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11773890\"></a>Benito AI, Furlong T, Martin PJ, et al, &ldquo;Sirolimus (Rapamycin) for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo; <i>Transplantation</i>, 2001, 72(12):1924-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/11773890/pubmed\" target=\"_blank\" id=\"11773890\">11773890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bissler JJ, McCormack FX, Young LR, et al, &ldquo;Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):140-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/18184959/pubmed\" target=\"_blank\" id=\"18184959\">18184959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costanzo MR, Dipchand A, Starling R, et al, &ldquo;The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients,&rdquo; <i>J Heart Lung Transplant</i>, 2010, 29(8):914-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/20643330/pubmed\" target=\"_blank\" id=\"20643330\">20643330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16042691\"></a>Couriel DR, Saliba R, Escalon MP, et al, &ldquo;Sirolimus in Combination With Tacrolimus and Corticosteroids for the Treatment of Resistant Chronic Graft-Versus-Host Disease,&rdquo; <i>Br J Haematol</i>, 2005, 130(3):409-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/16042691/pubmed\" target=\"_blank\" id=\"16042691\">16042691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cutler C, Kim H, Hochberg E, et al, &quot;Sirolimus and Tacrolimus Without Methotrexate as Graft-Versus-Host Disease Prophylaxis After Matched Related Donor Peripheral Blood Stem Cell Transplantation,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2004, 10(5):328-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/15111932/pubmed\" target=\"_blank\" id=\"15111932\">15111932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17138818\"></a>Cutler C, Li S, Ho VT, et al, &ldquo;Extended Follow-Up of Methotrexate-Free Immunosuppression Using Sirolimus and Tacrolimus in Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation,&rdquo; <i>Blood</i>, 2007, 109(7):3108-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/17138818/pubmed\" target=\"_blank\" id=\"17138818\">17138818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21525172\"></a>Davies DM, de Vries PJ, Johnson SR, et al, &ldquo;Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial,&rdquo; <i>Clin Cancer Res</i>, 2011, 17(12):4071-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/21525172/pubmed\" target=\"_blank\" id=\"21525172\">21525172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ettinger RB and Grimm EM, &ldquo;Safety and Efficacy of TOR Inhibitors in Pediatric Renal Transplant Recipients,&rdquo; <i>Am J Kidney Dis</i>, 2001, 38(4 Suppl 2):22-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/11583941/pubmed\" target=\"_blank\" id=\"11583941\">11583941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Euvrard S, Morelon E, Rostaing L, et al, &ldquo;Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation,&rdquo; <i>N Engl J Med</i>, 2012, 367(4):329-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/22830463/pubmed\" target=\"_blank\" id=\"22830463\">22830463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17919619\"></a>Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. <i>J Heart Lung Transplant</i>. 2007;26(10):998-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/17919619/pubmed\" target=\"_blank\" id=\"17919619\">17919619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16297793\"></a>Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. <i>J Heart Lung Transplant</i>. 2005;24(11):1863-1867.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/16297793/pubmed\" target=\"_blank\" id=\"16297793\">16297793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan BD, &ldquo;Efficacy of Sirolimus Compared With Azathioprine for Reduction of Acute Renal Allograft Rejection: A Randomised Multicentre Study. The Rapamune US Study Group,&rdquo; <i>Lancet</i>, 2000, 356(9225):194-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/10963197/pubmed\" target=\"_blank\" id=\"10963197\">10963197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>American Journal of Transplantation. </i>2009; 9(Suppl 3):S1&ndash;S157.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12792493\"></a>King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. <i>Transplantation</i>. 2003;75(9):1437-1443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/12792493/pubmed\" target=\"_blank\" id=\"12792493\">12792493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16364861\"></a>Kushwaha SS, Khalpey Z, Frantz RP, et al, &ldquo;Sirolimus in Cardiac Transplantation: Use as a Primary Immunosuppressant in Calcineurin Inhibitor-Induced Nephrotoxicity,&rdquo; <i>J Heart Lung Transplant</i>, 2005, 24(12):2129-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/16364861/pubmed\" target=\"_blank\" id=\"16364861\">16364861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12742978\"></a>Mancini D, Pinney S, Burkhoff D, et al, &ldquo;Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy,&rdquo; <i>Circulation</i>, 2003, 108(1):48-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/12742978/pubmed\" target=\"_blank\" id=\"12742978\">12742978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCormack FX, Inoue Y, Moss J,et al, &ldquo;Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis,&rdquo; <i>N Engl J Med</i>, 2011, 364(17):1595-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/21410393/pubmed\" target=\"_blank\" id=\"21410393\">21410393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDonald AS, &ldquo;A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts. RAPAMUNE Global Study Group,&rdquo; <i>Transplantation</i>, 2001, 71(2):271-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/11213073/pubmed\" target=\"_blank\" id=\"11213073\">11213073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18025531\"></a>Raichlin E, Bae JH, Khalpey Z, et al, &ldquo;Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation,&rdquo; <i>Circulation</i>, 2007, 116(23):2726-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/18025531/pubmed\" target=\"_blank\" id=\"18025531\">18025531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17713429\"></a>Raichlin E, Khalpey Z, Kremers W, et al, &ldquo;Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients,&rdquo; <i>Transplantation</i>, 2007, 84(4):467-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/17713429/pubmed\" target=\"_blank\" id=\"17713429\">17713429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapamune (sirolimus) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sifontis NM, Coscia LA, Constantinescu S, et al, &ldquo;Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus,&rdquo; <i>Transplantation</i>, 2006, 82(12):1698-1702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/17198262/pubmed\" target=\"_blank\" id=\"17198262\">17198262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11983543\"></a>Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. <i>J Heart Lung Transplant</i>. 2002;21(5):540-546.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/11983543/pubmed\" target=\"_blank\" id=\"11983543\">11983543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19570961\"></a>Stacchiotti S, Marrari A, Tamborini E, et al, &ldquo;Response to Imatinib Plus Sirolimus in Advanced Chordoma,&rdquo; <i>Ann Oncol</i>, 2009, 20(11):1886-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/19570961/pubmed\" target=\"_blank\" id=\"19570961\">19570961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stenton SB, Partovi N, and Ensom MH, &ldquo;Sirolimus: The Evidence for Clinical Pharmacokinetic Monitoring,&rdquo; <i>Clin Pharmacokinet</i>, 2005, 44(8):769-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/16029064/pubmed\" target=\"_blank\" id=\"16029064\">16029064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22207715\"></a>Topilsky Y, Hasin T, Raichlin E, et al, &ldquo;Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation,&rdquo; <i>Circulation</i>, 2012, 125(5):708-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/22207715/pubmed\" target=\"_blank\" id=\"22207715\">22207715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al, &ldquo;Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors,&rdquo; <i>J Clin Oncol</i>, 2010, 28(5):835-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/20048174/pubmed\" target=\"_blank\" id=\"20048174\">20048174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16699448\"></a>Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. <i>Transplantation</i>. 2006;81(9):1234-1248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/16699448/pubmed\" target=\"_blank\" id=\"16699448\">16699448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22776430\"></a>Zuckermann A, Keogh A, Crespo-Leiro MG, et al, &ldquo;Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency,&rdquo; <i>Am J Transplant</i>, 2012, 12(9):2487-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sirolimus-drug-information/abstract-text/22776430/pubmed\" target=\"_blank\" id=\"22776430\">22776430</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10329 Version 198.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709411\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221226\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F221227\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221253\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221230\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221242\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F221231\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F221232\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F221233\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221201\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221186\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50215677\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11310396\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F221204\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133426\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221203\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471667\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4288698\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221193\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221207\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F221246\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221195\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F221222\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221197\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F221210\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4288699\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F221199\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F221202\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F221206\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221209\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F221212\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10329|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sirolimus-patient-drug-information\" class=\"drug drug_patient\">Sirolimus: Patient drug information</a></li><li><a href=\"topic.htm?path=sirolimus-pediatric-drug-information\" class=\"drug drug_pediatric\">Sirolimus: Pediatric drug information</a></li></ul></div></div>","javascript":null}